Open Access. Powered by Scholars. Published by Universities.®
Medicinal and Pharmaceutical Chemistry Commons™
Open Access. Powered by Scholars. Published by Universities.®
- Keyword
- Publication
- Publication Type
Articles 1 - 2 of 2
Full-Text Articles in Medicinal and Pharmaceutical Chemistry
Lack Of Cross-Reactivity Allergy Following A Switch From Alirocumab To Evolocumab, Matthew D. Stryker, Michael Kane, Robert Busch
Lack Of Cross-Reactivity Allergy Following A Switch From Alirocumab To Evolocumab, Matthew D. Stryker, Michael Kane, Robert Busch
Excerpts in Pharmacy Research Journal
The proprotein convertase subtilisin/kexin type 9 (PCSK9) gene and gain-of-function mutations were first described in 2003. The gain-of-function mutations observed were associated with low-density lipoprotein-cholesterol (LDL-C) levels in the 400’s, in addition to premature cardiovascular disease. Subsequent loss-of-function experiments conducted in mice demonstrated marked reductions in plasma cholesterol levels in the absence of PCSK9. Physiologically, PCSK9 serves as a chaperone protein and functions to reduce low-density lipoprotein (LDL) receptor recycling; consequently, less LDL-C is removed from circulation and serum lipid concentrations become elevated. Inhibition of PCSK9 prevents LDL receptor degradation and preserves receptor recycling to the hepatocyte surface; this in …
A Comparison Of The Effect Of Intermittent And Continuous Infusion Of Meropenem On The Prevalence Of Nausea In Pediatric Cystic Fibrosis Patients, Marissa Cushing, Juanita A. Draime, Bao-Ngoc Ho, Jordan Nicholls, Bethany Sibbitt, Rebecca Widder, Rebecca J. Gryka, Denise S. Simpson
A Comparison Of The Effect Of Intermittent And Continuous Infusion Of Meropenem On The Prevalence Of Nausea In Pediatric Cystic Fibrosis Patients, Marissa Cushing, Juanita A. Draime, Bao-Ngoc Ho, Jordan Nicholls, Bethany Sibbitt, Rebecca Widder, Rebecca J. Gryka, Denise S. Simpson
Pharmacy and Nursing Student Research and Evidence-Based Medicine Poster Session
Cystic Fibrosis (CF) is a genetic disease, leading to changes of membrane secretions causing obstruction of smaller airways. CF patients often develop pulmonary infections and require antibiotic treatment. Meropenem is a broad spectrum beta lactam that acts by lysing microbes through interfering with bacterial cell wall synthesis. Although a safe and effective treatment, data on pediatric patients is limited.